Biopharma Vital Signs – Part 2: Emerging Trends - Top-Institutions - MDSpire

Biopharma Vital Signs – Part 2: Emerging Trends

Industry experts discuss the trends reshaping biotech and biopharma development – from complex modalities and manufacturing pressures to AI, funding constraints, and the growing need to plan for commercialization earlier

  • June 26, 2026

  • 10 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Harvard University
    Harvard University

    Cambridge, Massachusetts

    Key Differentiators

    • Pharmacology
    • Toxicology

  • #2

    University of California, San Diego
    University of California, San Diego

    La Jolla, California

    Key Differentiators

    • Pharmacology
    • Toxicology

Original Source(s)

Biopharma Vital Signs – Part 2: Emerging Trends

  • June 26, 2026

Related Content

Intravoxel incoherent motion combined with conventional MRI for the differentiation of benign, intermediate, and malignant fibrous soft-tissue tumors

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study

Epidemiology of bone cancer in Saudi Arabia: a nationwide population-based study (2004–2020)